MEI Pharma Analyst Ratings
MEI Pharma Analyst Ratings
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a maintained with a price target of $5.00 to $2.00. The current price MEI Pharma (MEIP) is trading at is $0.29, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/13/2023 | 599.3% | HC Wainwright & Co. | $5 → $2 | Maintains | Buy |
| 02/08/2023 | -65.03% | Jefferies | $0.4 → $0.1 | Downgrades | Hold → Underperform |
| 12/06/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 03/25/2022 | 1298.6% | BTIG | $11 → $4 | Maintains | Buy |
| 03/25/2022 | 948.95% | Truist Securities | $8 → $3 | Maintains | Buy |
| 03/25/2022 | 1648.25% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/25/2022 | 599.3% | Wells Fargo | $13 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/25/2022 | 599.3% | Stifel | $6 → $2 | Downgrades | Buy → Hold |
| 03/25/2022 | 249.65% | Jefferies | $4 → $1 | Downgrades | Buy → Hold |
| 02/03/2022 | 1298.6% | Jefferies | → $4 | Initiates Coverage On | → Buy |
| 05/29/2020 | 5494.41% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/13/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/20/2018 | 3396.5% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/27/2018 | 2347.55% | Stifel | $2.5 → $7 | Upgrades | Hold → Buy |
| 07/13/2018 | 4095.8% | SunTrust Robinson Humphrey | → $12 | Initiates Coverage On | → Buy |
| 06/06/2018 | — | Wells Fargo | Upgrades | Market Perform → Outperform | |
| 04/12/2018 | 2347.55% | Laidlaw & Co. | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 02/13/2023 | 599.3% | HC 溫賴特 & 有限公司. | 5 美元 → 2 美元 | 維護 | 購買 |
| 02/08/2023 | -65.03% | 富瑞集團 | 0 美元 → 0.1 美元 | 降級 | 保持 → 表現不足 |
| 12/06/2022 | — | BTIG | 降級 | 購買 → 中性 | |
| 12/06/2022 | — | 真理證券 | 降級 | 購買 → 持有 | |
| 03/25/2022 | 1298.6% | BTIG | 十一美元 → 4 美元 | 維護 | 購買 |
| 03/25/2022 | 948.95% | 真理證券 | 8 美元 → 3 美元 | 維護 | 購買 |
| 03/25/2022 | 1648.25% | HC 溫賴特 & 有限公司. | 10 美元 → 5 美元 | 維護 | 購買 |
| 03/25/2022 | 599.3% | 富國銀行 | 十三美元 → 2 美元 | 降級 | 超重 → 同等體重 |
| 03/25/2022 | 599.3% | 斯蒂弗 | 6 美元 → 2 美元 | 降級 | 購買 → 持有 |
| 03/25/2022 | 249.65% | 富瑞集團 | 4 美元 → 1 美元 | 降級 | 購買 → 持有 |
| 2022 年 3 月 2 日 | 1298.6% | 富瑞集團 | → 4 美元 | 啟動覆蓋範圍 | → 購買 |
| 2020 年 5 月 29 日 | 5494.41% | 太陽信託羅賓遜·漢弗萊 | → 十六美元 | 啟動覆蓋範圍 | → 購買 |
| 02/13/2019 | — | BTIG | 啟動覆蓋範圍 | → 購買 | |
| 12/20/2018 | 3396.5% | HC 溫賴特 & 有限公司. | → 10 美元 | 啟動覆蓋範圍 | → 購買 |
| 2018 年 7 月 27 日 | 2347.55% | 斯蒂弗 | 2.5 美元 → 7 美元 | 升級 | 持有 → 購買 |
| 2018 年 7 月 13 日 | 4095.8% | 太陽信託羅賓遜·漢弗萊 | → 十二美元 | 啟動覆蓋範圍 | → 購買 |
| 06/06/2018 | — | 富國銀行 | 升級 | 市場表現 → 跑贏大市 | |
| 2018 年 12 月 4 日 | 2347.55% | 萊德洛 & 有限公司. | → 7 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for MEI Pharma (MEIP)?
MEI 製藥（MEIP）的目標價格是多少？
The latest price target for MEI Pharma (NASDAQ: MEIP) was reported by HC Wainwright & Co. on February 13, 2023. The analyst firm set a price target for $2.00 expecting MEIP to rise to within 12 months (a possible 599.30% upside). 10 analyst firms have reported ratings in the last year.
韋萊特有限公司於 2023 年 2 月 13 日報導了 MEI 製藥（納斯達克代碼：MEIP）的最新價格目標。該分析師公司設定了 2.00 美元的價格目標，預計 MEIP 將在 12 個月內上升（可能是 599.30％ 的上漲情況）。去年有 10 家分析師公司報告了評級。
What is the most recent analyst rating for MEI Pharma (MEIP)?
MEI 製藥 (MEIP) 的最新分析師評級為何？
The latest analyst rating for MEI Pharma (NASDAQ: MEIP) was provided by HC Wainwright & Co., and MEI Pharma maintained their buy rating.
MEI 製藥公司（納斯達克股票代碼：MEIP）的最新分析師評級由 HC Wainwright & Co. 提供，MEI 製藥維持其購買評級。
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
MEI 製藥（MEIP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on February 13, 2023 so you should expect the next rating to be made available sometime around February 13, 2024.
分析師在進行廣泛的研究後到達股票評級，其中包括通過公共財務報表，與 MEI Pharma 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。最後一個評分為 MEI 製藥公司提交 2 月 13, 2023 所以你應該期望下一個評級將在二月左右的某個時候提供 13, 2024.
Is the Analyst Rating MEI Pharma (MEIP) correct?
分析師評級 MEI 製藥公司 (MEIP) 是否正確？
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a maintained with a price target of $5.00 to $2.00. The current price MEI Pharma (MEIP) is trading at is $0.29, which is out of the analyst's predicted range.
儘管評級是主觀的並且將會發生變化，但最新的 MEI 製藥（MEIP）評級維持，目標價格為 5.00 美元至 2.00 美元。目前的價格美醫藥 (MEIP) 的交易價格為 $0.29, 這是超出了分析師的預測範圍.
譯文內容由第三人軟體翻譯。
